inside sources print logo
Get up to date Delaware Valley news in your inbox

KALAVRITINOS: Biden’s SOTU Shows How Far Democrats Are Willing To Socialize Medicine

President Joe Biden’s State of the Union address was his opportunity to promote his “successes” and lay out his roadmap. In touting the so-called Inflation Reduction Act (IRA) he wasted no breath, claiming it was a victory for patients due to the law’s new prescription drug price controls. That was one of many “misstatements” as it has been mislabeled and will soon hurt seniors with a raid on Medicare and Americans losing access to drugs that are currently in development.

After this election-year bill was passed, Democrats falsely declared victory over high drug prices. Sadly, too many Republicans were silent. The average American deserves to fully understand the IRA, who it really rewards, and how the law is nothing less than an ideological push aimed at furthering socialized medicine before delivering results.

In recent days culminating in the State of the Union address, the president claimed “historic progress” “on lowering health care costs under his watch, including steps to strengthen Medicare, Medicaid, and the Affordable Care Act (ACA)” and touting the new prescription drug provisions, which will mandate Medicare be able to negotiate drug prices.” His definition of progress is giving seniors fewer choices, innovators fewer incentives, redefining “negotiation” as “extortion,” expanding Obamacare and Medicaid and raiding Medicare for green new deal projects.

What the IRA actually does is not as straightforward as Democrats and aligned groups like AARP and left-wing think tanks would have you believe. The nasty side-effects of price controls on Medicare Part D drugs are impossible to ignore, considering this policy stunts American efforts to cure illnesses, harms drug access, and reduces options for patients relying on carefully designed drug regimens. How badly will this hurt the creation of new and life-changing drugs? A University of Chicago issue brief showed the law would result in a whopping 135 fewer new drugs, impacting the lives of 2.47 million patients. Four innovator-sponsored clinical trials have already been canceled in the first four months. How many of those drugs would have been breakthrough cures? How many would have changed the lives of patients hoping for better treatments?

Biden’s IRA victory lap does little to alleviate the unnecessary burden on Americans who are struggling with their health. America ought to lead the way in creating new and innovative treatments. The IRA even cuts back on the Trump administration’s anti-kickback regulations that limited the power of PBMs and would have lowered drug list prices. And perhaps it was a coincidence that President Biden conveniently forgot to mention that the IRA doles out billions in Medicare savings to giant health insurance companies.

It is truly something. On one hand, the Democrats crafted the IRA as a step toward an EU-style healthcare system. On the other hand, the law also hands taxpayer funding intended for Medicare to their friends in the insurance-PBM industry. Over $270 billion gone from Medicare in the name of socialist price controls, gifted to giant insurance corporations and PBMs. Isn’t that a slap in the face of people relying on Medicare?

All this being said, Biden, his party, big insurers, and supposedly “non-partisan” organizations are hijacking America’s health system for both personal benefit and ideological reasons. In the case of outside parties, they may have supported the IRA to earn a windfall. For the Democrats, moving healthcare closer to what citizens have in London and Toronto is becoming more and more their guiding light. As the IRA will soon prove, socialized medicine, with its rationed care and fewer choices for Americans, will have serious consequences for all Americans.

Please follow DVJournal on social media: Twitter@DVJournal or

New Study Gives Medicare Advantage Edge in Quality of Care

Medicare Advantage is the best bet for seniors looking at their options as the open enrollment period begins, according to a new study published by the “Journal of the American Medical Association (JAMA) Health Forum.”Medicare Advantage, also known as Medicare Part C, gives seniors a choice about how to get their medical services delivered over the traditional fee-for-service Medicare plan. According to the JAMA study, that choice also gives seniors better value and better care.

Examining data from nearly two million Medicare beneficiaries, the JAMA-published study concluded that “those enrolled in MA had lower rates of hospital stays, emergency department visits, and 30-day readmissions.” Additionally, the study noted that “[a]mong Medicare beneficiaries with complex care needs, those enrolled in MA had lower rates of acute care utilization, suggesting that managed care activities in MA may influence the nature and quality of care provided to these beneficiaries.”

Medicare Advantage provides health care plans offered by approved private coverage providers. Unlike government-run fee-for-service Medicare, Medicare Advantage plans can cover additional services that seniors rely on and depend upon, such as prescription drugs and routine eye and dental care.

The option currently enjoys broad backing in the halls of Congress, with 63 members of the U.S. Senate signing a letter on the program’s behalf.

“We write to express bipartisan support for the Medicare Advantage program and the high-quality, affordable care it provides to over 27 million older adults and people with disabilities,” the letter read, signed by members as ideologically diverse as Sens. Mazie Hirono (D-Hawaii) and Tommy Tuberville (R-Ala.)

In September, the House of Representatives passed a bill on a voice vote to make it easier for seniors using MA to get approval for treatment and prescriptions.

Traditional fee-for-service Medicare does not limit seniors’ out-of-pocket costs and copays. As a result, beneficiaries pay nearly $2,000 more per year in total healthcare-related costs than those enrolled in Medicare Advantage plans.

Because Medicare Advantage relies on the private sector, some more progressive politicians oppose the option and have tried to limit its expansion or even kill it entirely. The progressive magazine “The American Prospect” wrote about Medicare advantage, and their opposition to it, in a piece headlined “The Dark History of Medicare Privatization.”

Some members of Congress have urged the Centers for Medicare and Medicaid (CMS) to protect eligible Medicare beneficiaries who might be subject to aggressive and potentially predatory marketing tactics related to the sale of Medicare Advantage plans or other insurance products.

However, based on the data, it appears seniors are satisfied with both the coverage and the quality of care received.

According to the non-partisan Kaiser Family Foundation, Medicare Advantage enrollment has doubled over the last 15 years. Currently, 32 percent of Medicare-eligible Granite State seniors choose Medicare Advantage over traditional fee-for-service Medicare.

Reports from the Better Medicare Alliance, a research and advocacy group, indicate 95 percent of Medicare Advantage beneficiaries are satisfied with their network of care and a full 88 percent say Medicare Advantage gives them more flexibility and choice.

A separate study published by JAMA found Medicare Advantage beneficiaries received 9.2 percent fewer “costly, potentially harmful” low-value services than fee-for-service Medicare enrollees. In other words, Medicare Advantage beneficiaries received better-quality care.

Please follow DVJournal on social media: Twitter@DVJournal or

GOLDBERG: Medicare Will Use Death Panels to Set Drug Prices

Under the Inflation Reduction Act, death panels will determine what medicines Medicare should pay for to free up money for other government spending.

That’s not hyperbole. Under the Inflation Reduction Act (IRA), seniors still pay retail prices. (And only the 3 percent of Medicare beneficiaries who spend more than $2,000 out of pocket will see costs capped.) Medicare will determine the cost-effectiveness of medicine to generate discounts in the form of $250 billion in cash rebates. Specifically, under IRA, Medicare will set prices based on how much a medicine costs to add an additional year of healthy living (called a quality-adjusted year, or QALY) compared to or on top of existing therapies.

While Medicare can’t use cost-effectiveness research (CER) to “treat extending the life of elderly, disabled or terminally ill individuals as less valuable,” it can be used to establish at what price a drug should be made available.

CER is already approved by states to limit access to new medicines under Medicaid.  The therapies include those for cystic fibrosis, rare cancers and sickle cell anemia; treatments that primarily help minorities, the disabled and the terminally ill. Pharmacy benefit managers who administer the Medicare drug benefit and the Veterans Health Administration already use CER to negotiate drug prices.

They all contract with a group called the Institute for Clinical and Economic Review (ICER) to carry out CER.  Since 2016, ICER has deemed only 3 medicines out of nearly 100 evaluated for rare and life-threatening diseases cost-effective at or near the average 20 percent rebated price. Most other drug prices would have to be cut by 50 percent to 100 percent. That includes medicines for multiple myeloma, sickle cell anemia, ALS and chronic kidney disease.

Indeed, ICER counts the ability of a new drug to improve well-being by extending life as a cost, not a benefit. ICER claimed a medicine to reduce anemia from chronic kidney disease was not cost-effective “because more people will live longer, more people will be at risk of needing care for end-organ damage, increasing the cost of keeping people alive.”

Similarly, it noted that new sickle cell anemia drugs reduce the “risk of death from these chronic conditions,” making them “less cost-effective.” Incredibly ICER “chose to use the highest estimates of the risk of death to give an optimistic estimate of the (cost-effectiveness) of the treatment effect.”

Further, ICER claims that new medicines for rare diseases, especially those afflicting children, are too costly at any price. As ICER president Steve Pearson wrote, orphan drug spending places an “undue burden … on others for the sake of a few.” Specifically, ICER asserts, “The opportunity cost of supporting the use of ultra-orphan drugs necessitates that patients with a more common disease, for which a cost-effective treatment is available, are denied treatment.”

Most drugs for rare diseases also reduce the risk and severity of common diseases. While curative gene and cell therapies may cost hundreds of thousands of dollars, new methods of hedging financial risk and paying for treatments over time make their cost affordable. And in any event, since we can save $800 billion by eliminating wasteful health spending, why do ICER and CER target dying children to save money?

Because it’s a quick way to generate lots of money for other government programs.

Indeed, in 2016 ICER asserted:  “When we’re paying for drugs and don’t know the drug’s value, we will be “siphoning off resources for other things we need like better schools and more resources for local police, roads and bridges.”  Or, in the case of the IRA, siphoning money for 87,000 IRS agents and $249 billion in climate change tax credits for corporations. Ultimately, ICER and other comparative effectiveness firms are de facto death panels deployed by the Democrats to turn dying patients into cash cows for corporate welfare.

Please follow DVJournal on social media: Twitter@DVJournal or